Information Provided By:
Fly News Breaks for December 17, 2018
NITE
Dec 17, 2018 | 06:59 EDT
Barclays analyst Gena Wang started Nightstar Therapeutics with an Overweight rating and $28 price target. The company's current enterprise value of $250M does not reflect the potential of its two leading programs in inherited retinal disorders, Wang tells investors in a research note. She estimates total probability-unadjusted peak sales at ~$1B after considering anticipated competition for the two programs. The analyst sees a "reasonable chance" of success for both NSR-REP1 in choroideremia and NSR-RPGR in X-linked retinal pigmentosa. Data readouts in 2019/20 should further characterize the product profiles and generate potential upside, says Wang.
News For NITE From the Last 2 Days
There are no results for your query NITE